<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?</h2>
    <div class="badge">2025-09-15T13:53:00+00:00</div>
    <ul>
      <li>Libtayo’s performance has been good so far, as sales totaled $661.6 million in the first half of 2025, up 18% year over year.</li>
<li>Image Source: Zacks Investment Research The bottom-line estimate for 2025 has moved up $2.22 to $38.71 over the past 60 days and the same for 2026 has increased 63 cents.</li>
<li>Shares of Regeneron Pharmaceuticals (REGN) have lost 21.1% year to date against the industry’s growth of 5.2%.</li>
<li>Eylea HD sales in the United States surged 29% in the second quarter due to higher sales volumes driven by increased demand.</li>
<li>REGN currently carries a Zacks Rank #3 (Hold).</li>
<li>Today, you can download 7 Best Stocks for the Next 30 Days.</li>
<li>Roche has designed Vabysmo to block pathways involving Ang-2 and VEGF-A.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?\n• Libtayo’s performance has been good so far, as sales totaled $661.6 million in the first half of 2025, up 18% year over year.\n• Image Source: Zacks Investment Research The bottom-line estimate for 2025 has moved up $2.22 to $38.71 over the past 60 days and the same for 2026 has increased 63 cents.\n• Shares of Regeneron Pharmaceuticals (REGN) have lost 21.1% year to date against the industry’s growth of 5.2%.\n• Eylea HD sales in the United States surged 29% in the second quarter due to higher sales volumes driven by increased demand.\n• REGN currently carries a Zacks Rank #3 (Hold).\n• Today, you can download 7 Best Stocks for the Next 30 Days.\n• Roche has designed Vabysmo to block pathways involving Ang-2 and VEGF-A." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/regn-loses-21-1-date-135300786.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>